Abstract: The application is directed a composition comprising organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof, and methods of using the same. In certain aspects the application is directed to glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof; and an organic acid; wherein the molar ratio is about 0.5-1:1. The composition can further comprises a bicarbonate salt, wherein the molar ratio is about 0.1-0.5:0.5-1:1.

Abstract: The application is directed a composition comprising organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof, and methods of using the same. In certain aspects the application is directed to glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof; and an organic acid; wherein the molar ratio is about 0.5-1:1. The composition can further comprises a bicarbonate salt, wherein the molar ratio is about 0.1-0.5:0.5-1:1.

Abstract: Compositions and methods are provided for mitigating the effects of alcohol by delaying alcohol absorption and/or reducing blood alcohol concentration, and/or for delaying gastric emptying.

Abstract: Potassium carbonate, Cocoglucoside, a Preservative, Sodium gluconate, and Demineralized water. The formulation is intended to be dispensed and/or applied from a spray bottle or wet wipe. Demineralized water is used as a solvent and has a concentration of approximately up to approximately 99 percent of the weight by percentage. Potassium carbonate is the uric acid remover, and has a concentration of approximately 1-25 percent of the formulation. Cocoglucoside or Coco Glucoside is a natural, non-ionic, surfactant and acts as a cleaner and has a concentration of approximately 0.1-15 percent. Sodium gluconate is used as a chelating agent and has a concentration of approximately 0.1-25 percent. A chemical preservative may be added the formulation in any amount or percentage as desired or in any amount or sufficient quantity desired for the preservation or shelf life of the product.

Abstract: The invention provides formulations and a process for disinfection, cleansing, and establishing a residual biostatic surface protection for dentures and removable oral appliances. These appliances include complete and partial dentures, removable dental applications, and other products used in an individual's mouth.

Abstract: Potassium carbonate, Cocoglucoside, a Preservative, Sodium gluconate, and Demineralized water. The formulation is intended to be dispensed and/or applied from a spray bottle or wet wipe. Demineralized water is used as a solvent and has a concentration of approximately up to approximately 99 percent of the weight by percentage. Potassium carbonate is the uric acid remover, and has a concentration of approximately 1-25 percent of the formulation. Cocoglucoside or Coco Glucoside is a natural, non-ionic, surfactant and acts as a cleaner and has a concentration of approximately 0.1-15 percent. Sodium gluconate is used as a chelating agent and has a concentration of approximately 0.1-25 percent. A chemical preservative may be added the formulation in any amount or percentage as desired or in any amount or sufficient quantity desired for the preservation or shelf life of the product.

Abstract: The present invention includes compositions and methods for the treatment, softening and removal of ear wax by administering to the ear a solution of a semi-fluorinated alkane according to the formula: RFRH or RFRHRF, wherein RF is a perfluorinated hydrocarbon segment with 20 or less carbon atoms, and RH is a non-fluorinated hydrocarbon segment with 3 to 20 carbon atoms.

Abstract: The present invention relates to a medical solution. According to the invention the ready-for-use solution comprises phosphate in a concentration of 1.0-2.8 mM, is sterile and has a pH of 6.5-7.6. The present invention further relates to a method for producing the medical solution and the use thereof.

Abstract: A method of stabilizing aqueous solutions of antimicrobial silanol quaternary ammonium compounds (SQACs) from premature polymerization where the stabilizing agent is selected from a list of antimicrobial, naturally occurring, renewable, volatile, liquid phytochemical essential oils that easily form crystal clear microemulsions when water is added to the concentrated SQAC/essential oil mixture. These non-foaming oil-in-water microemulsions have excellent long term storage stability, remain very low in viscosity and do not phase or precipitate for many months. Many essential oils found to be useful in this process are non-toxic food additives having pleasant scents, have low flammability yet are volatile enough to evaporate upon cure down of the SQAC, resulting in a higher concentration of SQAC in the cured, antimicrobial film.

Abstract: Antimicrobial treated articles and compounds. The article includes a substrate and an antimicrobial mixture of an effective amount of at least one antimicrobial silanol quaternary ammonium compound, at least one essential oil and the balance water. In one embodiment, the antimicrobial mixture is forming in a reaction medium for mixing the at least one antimicrobial silanol quaternary ammonium compound and the at least one essential oil together prior to treating the substrate.

Abstract: The present invention relates to a solution for peritoneal dialysis consisting of one or more separate solutions. A treatment free of side-effects with a simultaneous lowering of blood pressure can be achieved in that the solution contains sodium ions in a concentration in the region from 121 to 129 mmol/l, preferably at 125 mmol/l. The invention furthermore relates to a double-chambered pouch having a peritoneal dialysis solution consisting of two separate solutions which consists of a plastic pouch in which a first chamber with the first separate solution and a second chamber with the second separate solution are arranged adjacent to one another, with both chambers being separated from one another by a weld seam dimensioned such that it opens on pressure onto one of the chambers filled with liquid so that the content of the two chambers can be mixed with one another.

Abstract: An outdoor cleaning concentrate composition having improved dirt and stain cleaning properties on outdoor surfaces, that is less corrosive and capable of being used with a water spraying system; and that is environmentally friendly. The outdoor cleaning concentrate composition includes the following components: a surfactant selected from the group consisting of alkyl glucosides, alkyl carboxylates, alkyl polyoxyethylenes, alkyl polysaccharides, alkylamine ethoxylates, amphoterics, amine oxides, polyalkylene glycol, sarcosines and sarcosinates; a fungicide; a chelating agent; a disinfectant; and a specific pH range. The surfactant is preferably an alkyl glucoside; more preferably, caprylyl/decyl glucoside. The fungicide is preferably potassium bicarbonate, while the disinfectant is preferably potassium carbonate.

Abstract: A method is provided for attenuating free radical formation resulting from a bodily insult. The method includes administering bicarbonate to the body of a subject at a dosage ranging from 1.5 mEq/kg of body weight to 5.0 mEq/kg of body weight within a 24-hour period.

Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one calcium salt, and optionally potassium salt, and magnesium salt. According to the invention said glucose and said at least one calcium salt, are present as anhydrous components in said dialysis acid precursor composition.

Abstract: The present invention relates to a combination of cajeput and extract from the plant Pimenta racemosa for use in preventing ornamental fish parasite infestation or removing ornamental fish parasites. The combination of cajeput and extract from the plant Pimenta racemosa is administered to the fish.

Abstract: An environmentally safe, non-phytotoxic pesticidal composition comprising natural plant oils geraniol and cedar oil and methods of controlling insects is provided.

Abstract: A short chain polypeptide having antioxidant activity is provided. The short chain polypeptide has 2 to 4 amino acids bonded to form a polypeptide chain having an amine-terminal end and a carboxyl terminal end; wherein a net charge of the short chain polypeptide is positive, the amino terminal amino acid is an amino acid selected from the group consisting of arginine, lysine and histidine, the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group. A method to prepare a composition having antioxidant activity and a composition having antioxidant activity are also provided.

Abstract: There is disclosed a method for treating a plant infection caused by a fungus of the class ascomycetes, comprising applying to the plant a combination of tea tree oil (TTO) and a synthetic fungicidal compound. Other embodiments are also disclosed.

Abstract: The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies.

Abstract: Parasiticidal aqueous suspension typically comprising from 1 to 15% by weight of silica and from 30 to 45% of alkali metal bicarbonate, and method for controlling the development of parasites on animals reared in buildings, according to which the animal's environment in the building is brought into contact with this aqueous suspension.

Abstract: An oral combination therapy or oral composition that protects orally administered exogenous leptin from the environment of the gastrointestinal tract, allowing delivery of the exogenous leptin to the bloodstream. The oral combination therapy includes (a) leptin or a leptin functional derivative; (b) a stomach acid-neutralizing agent such as a buffer; and (c) a pancreatic protease inhibitor that protects the exogenous leptin from degradation by pancreatic enzymes; and (d) a bile acid or a bile acid analog that facilitates absorption of the exogenous leptin. The oral combination therapy or oral composition may also include at least one agent that stimulates endogenous leptin secretion; as well as at least one agent capable of promoting, enhancing or improving adherence to treatment such as a sweetener or a satiety triggering agent.

Abstract: A feed supplement mixture for performance horses provides a high protein nutritional supply while lowering stress experienced by the horse, reduces the onset of ulcers in the horse's digestive tract and treats ulcers in horses already afflicted with ulcers by the introduction of a quantity of thiamine to reduce stress and sodium bicarbonate to raise the ph level of the feed and the horse's stomach content.

Abstract: The present invention relates to phytosanitary compositions with fungicidal properties that comprise a mixture of essential oils obtained from plants and agents with known fungicidal properties, such as alkali metal or ammonium bicarbonates, and compounds based on copper or the salts thereof, for use, principally, in contact-protection against fungal infections in cultivated plants and post-harvest, and also in other antifungal applications. In said compositions, the effect of the agents that have known fungicidal properties is potentiated synergistically by the aforementioned essential oils. The present invention also relates to the use of said essential oils as potentiators for agents with known fungicidal properties.

Abstract: In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.

Abstract: Aqueous parasiticidal suspension typically comprising from 1 to 15% by weight of silica and from 30 to 45% by weight of sodium bicarbonate and method for controlling the development of parasites on animals raised in buildings, according to which the environment of the animal in the building is brought into contact with this aqueous suspension.

Abstract: A sodium bicarbonate product comprises particles containing sodium bicarbonate and an organic material that is a solid at ambient temperature. The particles have a structure comprised of individual crystallites of sodium bicarbonate attached together in the particle. More than 95% by volume of the particles have a size less than 200 ?m. Particles of the product are hollow and are formed of an outer shell of the crystallites. The product may be used, for example, as a leavening agent in the production of cooked foods. The product may be produced by spray drying a solution or slurry dissolved organic material and dissolved sodium bicarbonate. The sodium bicarbonate may be present as a suspension.

Abstract: The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy.

Abstract: Stable aqueous compositions of silane quaternary ammonium compounds are provided by diluting an alkanol solution of the silane quaternary ammonium compound in water with at least one nonionic surfactant. The weight ratio of the silane quaternary ammonium compound and nonionic surfactant is provided to yield a composition which can remain stable in dilute aqueous compositions, can be applied to any surface and dry quickly to provide an anti-microbial film. The addition of an alkali metal bicarbonate salt to the composition improves the anti-microbial properties as well as the drying time of the composition.

Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.

Abstract: The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.

Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one calcium salt, and optionally potassium salt, and magnesium salt. According to the invention said glucose and said at least one calcium salt, are present as anhydrous components in said dialysis acid precursor composition.

Abstract: Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in pediatric patients, leading to pulmonary edema. The methods include avoiding or discontinuing administration of inhaled nitric oxide to a pediatric patient determined to have pre-existing left ventricular dysfunction but who otherwise is a candidate for inhaled nitric oxide treatment (e.g., for pulmonary hypertension), and administering inhaled nitric oxide to pediatric patients who are candidates for such treatment and who are determined not to have pre-existing left ventricular dysfunction.

Abstract: A composition comprising at least one substance coated with an agent wherein the agent forms a liquid impermeable but gas permeable layer surrounding the said substance and preventing the passage of the said substance through said coating, wherein in-use the said substance is not released into solution in the body, and wherein said substance is selected from one or more of the group consisting of calcium phosphate, sodium chloride, potassium chloride, magnesium chloride, calcium carbonate, and sodium bicarbonate for use in the treatment of osteoporosis and other bone conditions.

Abstract: Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in pediatric patients, leading to pulmonary edema. The methods include avoiding or discontinuing administration of inhaled nitric oxide to a pediatric patient determined to have pre-existing left ventricular dysfunction but who otherwise is a candidate for inhaled nitric oxide treatment (e.g., for pulmonary hypertension), and administering inhaled nitric oxide to pediatric patients who are candidates for such treatment and who are determined not to have pre-existing left ventricular dysfunction.

Abstract: The present invention provides a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administered to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions or another single solution containing electrolyte salts. Glucose-like degradation and hydrolysis is avoided during sterilization and storage, while maintenance of a neutral mixture pH is achieved by the osmotic comprising a glucose polymer and/or glucose polymer derivative, and the pH of the first single solution being between 3.5 and 5.0. The present invention further discloses a twin-chambered pouch consisting of a plastic pouch with at least one first chamber and a second chamber, the first single solution being included in the first chamber and the second single solution being included in the second chamber.

Abstract: The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties.

Abstract: The present invention relates to a method of consuming a universal potent healing tonic. When consumed according to the method, of a host of medical ailments can be abated including cancer, arthritis, and insomnia.

Abstract: A rodenticidal composition comprising a carbon dioxide release agent and a carrier may be disclosed. A method of controlling rodents at a locus by applying the composition of the disclosure may be disclosed.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: Methods for providing post-operative pain control or relief to a patient are disclosed. Methods include, for example, administering bicarbonate to an area of a patient during a surgical or dental procedure, near completion of a surgical or dental procedure or immediately following a surgical or dental procedure, in an area previously administered or containing a regional or local anesthetic in an amount sufficient to provide the patient with pain control or relief for a period of time after the surgical or dental procedure.

Abstract: Particular aspects provide novel insecticide/miticide/fungicide compositions, and methods for using same for safe, environmentally friendly control of insects, mites and fungal pests in, e.g., gardening and commercial growing. Preferably, the compositions comprise organic or pure ingredients. Particular embodiments comprise: a fatty acid soap base (e.g., saponified soap with retained glycerin; or fatty acid salts with glycerin); at least one essential oil; an optional food oil; and a bicarbonate reagent, along with water. Additional embodiments comprise: a soap base, and/or glycerin or other suitable base; at least one organic or pure plant essential oil; an organic or pure food oil; and a bicarbonate reagent, along with water as diluent and carrier, and methods for using same. Further aspects provide a method for controlling mite and fungal pests with a single composition comprising, along with an aqueous carrier or diluent: a non-petroleum-based food oil; and a bicarbonate agent.

Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.

Abstract: The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and rheumatology. In one aspect, the invention provides pharmaceutical compositions for the treatment and/or prevention of osteoarthritis in mammals, particularly humans, comprising sodium bicarbonate and calcium gluconate, and optionally comprising one or more additional components. The invention also provides methods of treating or preventing osteoarthritis by administering to a mammal, preferably via intraarticular injection, one or more compositions of the invention.

Abstract: A solution having improved mold and mildew stain removing properties on hard surfaces, that is easier to handle (less corrosive and less malodorous) and that is environmentally friendly. The mold and mildew stain removing solution includes the following components: a surfactant selected from the group consisting of alcohol ethoxylates, alkyl sulfates, alkyl ether sulfates, alpha olefin sulfonates, alkyl phosphates, alkyl amidopropyl betaines, alkyl betaines, amphoacetates, amphoproprionates, amphosulfonates, amine oxides, alkanolamides, sulfosuccinates, and sultaines, a solvent, and at least one chelating agent. The solution may further comprise a hydrotrope, a diluent, a preservative, and/or a fungicide. The surfactant is preferably an alcohol ethoxylate. The hydrotrope is preferably lauramine oxide. The solvent is preferably a glycol ether. The chelating agents are preferably sodium gluconate and a solution of the trisodium salt of methyl glycine diacetic acid.

Abstract: The present invention relates to an oral composition comprising, in an orally acceptable carrier, from about 0.1% to about 5% zinc oxide; and from about 0.1% to about 5% of a source of carbonate ions selected from alkali metal and ammonium carbonates and bicarbonates. The molar ratio of carbonate ion to zinc ion is from about 0.05:1 to about 1:1. The composition has good antiplaque efficacy and taste. Preferred compositions are toothpastes.

Abstract: A method for the administration of nicotine, THC, tobacco, cannabidiol or a base alkaloid includes administering in the oral or nasal cavity an absorption conditioning unit having at least two agents selected from the group consisting of (a) a buffer agent, (b) a capturing agent, (c) a penetration agent, and (d) a thermal agent, to the mammal, and then administering by inhalation a bioactive agent selected from the group consisting of nicotine, THC, cannabidiol and a base alkaloid. The absorption conditioning unit may be in a dosage form not containing a drug. The absorption conditioning unit may create a pH in the oral cavity or nasal cavity of 7.8-10 for a period of ten minutes or more after administration, the dosage form not containing an acid and not containing a drug.

Abstract: The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy.

Abstract: A drug delivery system for the controlled release of a pharmaceutically-active compound by oral route comprises an intercalate of a layered double hydroxide having, before intercalation, layers of metal hydroxides, and having intercalated therein a pharmaceutically-active compound having at least one anionic group. A preferred layered double hydroxide is one that has layers which comprise [LiAl2(OH)6]+. The drug delivery system has use in the delivery of drugs such as 4-biphenylacetic acid, Diclofenac, Gemfibrozil, Ibuprofen, Naproxen, 2-Propylpentanoic acid and Tolfenamic acid.

Abstract: Textiles coated with aqueous compositions of silane quaternary ammonium compounds and alkali metal bicarbonates are provided with deodorization properties and protection from allergens, irritants, molds, dust mites, bacteria, and fungi.

Abstract: The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.